Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Francesco GelsominoGiuseppe LambertiMarcello TiseoDanilo RoccoGiulia PaselloFabiana Letizia CecereAntonio ChellaGiada GrilliMarcella MandruzzatoMichele TognettoMarina Chiara GarassinoMarianna MacerelliSilvia NovelloFausto RoilaIda ColantonioFrancesco GrossiMichelangelo FiorentinoAndrea ArdizzoniPublished in: Therapeutic advances in medical oncology (2020)
Therapeutic options in NSCLC with rare histology subtypes, to be assessed in specifically designed trials, are an unmet need. This trial will help elucidate the role of atezolizumab as a viable option in this setting.